Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dave Fredrickson
Pharma
As AZ hits $45B revenue goal, is Enhertu nearing a plateau?
Enhertu's new patient share in HER2-low breast cancer appears to have flattened, raising questions about the indication's real market opportunity.
Angus Liu
Feb 8, 2024 10:48am
AZ's first-in-class breast cancer approval marred by restriction
Nov 17, 2023 11:02am
AstraZeneca exec touts Enhertu's 'game-changing' SABCS showing
Dec 9, 2022 9:41am
AZ's oncology head talks up Tagrisso, Imfinzi potential
Apr 30, 2021 11:50am
AstraZeneca's Imfinzi strikes out again in head and neck cancer
Feb 5, 2021 11:44am
Love 'em or hate 'em, virtual medical meetings are here to stay
Dec 22, 2020 9:40am
